Scrip's Five Must-Know Things - Oct. 19, 2026
From Scrip Podcasts · 17:07
Show by Norstella
Join us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things. This episode covers insights for the business week ended Oct. 16, 2026. This time—Tremfya rises from Stelara’s ashes; Pfizer uses mature brands as testbeds; Chinese science shines in Q3 deals; autoimmune win and setback for Argenx; and Japan looks to restore biopharma competitiveness. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-IZOIOAJVX5ERZMYRIYPGPLUVFA/ This and all our other podcasts are available on the Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn. Any comments? [email protected]
More episodes of Scrip Podcasts
More episodes
- Strategic Intent: Lundbeck On Reimbursement, Risk And The Return Of Neuroscience
- Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast)
- Scrip's Five Must-Know Things: Madrigal Whistleblower Case, Lilly & Sanofi Hunting Deals
- Proof of Concept: The Money Is Back In RNA, But What Stands Between Headlines And Routine Medicine?
- Rethinking Risk: Why Early Evidence Strategy Matters for Emerging Biotechs
- Scrip's Five Must-Know Things: US COINS Impact, GSK's Oncology Turnaround, Lilly's KRAS Push
- Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast)
- Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Oct.26, 2026
- Scrip's Five Must-Know Things: Key ESMO Readouts, Next-Gen ADCs And Mid-Cap Winners
- Scrip Awards Podcast – Parabilis CEO Mathai Mammen Interview
PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.